Outcomes for Patients with Metastatic Renal Cell Carcinoma
Achieving a Complete Response on Targeted Therapy: A
Registry-based Analysis.

J 2016

Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis.

BUCHLER, Tomas, Zbyněk BORTLÍČEK, Alexandr POPRACH, Tomáš PAVLÍK, Veronika VESKRNOVA et. al.

Základní údaje

Originální název

Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis.

Autoři

BUCHLER, Tomas (203 Česká republika), Zbyněk BORTLÍČEK (203 Česká republika, garant, domácí), Alexandr POPRACH (203 Česká republika), Tomáš PAVLÍK (203 Česká republika, domácí), Veronika VESKRNOVA (203 Česká republika), Michaela HONZIRKOVA (203 Česká republika), Milada ZEMANOVA (203 Česká republika), Ondrej FIALA (203 Česká republika), Kateřina KUBÁČKOVÁ (203 Česká republika), Ondřej SLABÝ (203 Česká republika), Marek SVOBODA (203 Česká republika), Rostislav VYZULA (203 Česká republika), Ladislav DUŠEK (203 Česká republika, domácí) a Bohuslav MELICHAR (203 Česká republika)

Vydání

European Urology, Amsterdam, Elsevier Science Inc. 2016, 0302-2838

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 16.265

Kód RIV

RIV/00216224:14110/16:00088841

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.eururo.2015.12.031

UT WoS

000380754000024

Klíčová slova anglicky

Renal cell carcinoma; Targeted therapy; Complete response; Survival

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 27. 9. 2016 11:33, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

BACKGROUND: It is currently not known whether treatment with anti-vascular endothelial growth factor agents for metastatic renal cell carcinoma (mRCC) can be safely discontinued in patients achieving a complete response (CR). OBJECTIVE: To assess outcomes for patients with mRCC achieving CR on targeted therapy (TT) and the survival of patients discontinuing TT after CR. DESIGN, SETTING, AND PARTICIPANTS: A national registry was used to identify patients achieving CR during first-line TT using bevacizumab, sunitinib, sorafenib, or pazopanib. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Relationships with outcomes were analysed using a log-rank test. RESULTS AND LIMITATIONS: A total of 100 patients achieving CR were identified out of 2803 patients. The median time to CR was 10.1 mo. Median progression-free survival (PFS) from TT initiation was 3.8 yr (95% confidence interval [CI] 2.9-4.6 yr) and the 5-yr overall survival (OS) was 80% (95% CI 70-91%). Patients discontinuing TT within 1 mo after achieving CR and those continuing TT beyond CR had similar OS (CI for difference in 2-yr post-CR OS -13% to 19%; p=0.3) and PFS (CI for difference in 2-yr post-CR PFS -29% to 17%; p=0.7). The limitations include the retrospective, registry-based data analysis. CONCLUSIONS: Achievement of CR on TT for mRCC was associated with excellent long-term prognosis. No significant differences in post-CR survival were observed between patients discontinuing TT after the date of CR and those who continued on TT, although the wide CIs cannot exclude important differences between the groups. PATIENT SUMMARY: According to this registry-based analysis, patients with metastatic renal cancer with no signs of disease (complete response) after treatment with targeted agents experience excellent long-term survival even if the treatment does not continue beyond the date of complete response.

Návaznosti

NV15-34678A, projekt VaV

Název: Molekulární prognostické a prediktivní faktory u pacientů s metastatickým renálním karcinomem léčených tyrozinkinázovými inhibitory

Citovat

BUCHLER, Tomas, Zbyněk BORTLÍČEK, Alexandr POPRACH, Tomáš PAVLÍK, Veronika VESKRNOVA, Michaela HONZIRKOVA, Milada ZEMANOVA, Ondrej FIALA, Kateřina KUBÁČKOVÁ, Ondřej SLABÝ, Marek SVOBODA, Rostislav VYZULA, Ladislav DUŠEK a Bohuslav MELICHAR. Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis. European Urology. Amsterdam: Elsevier Science Inc., 2016, roč. 70, č. 3, s. 469-475. ISSN 0302-2838. Dostupné z: https://dx.doi.org/10.1016/j.eururo.2015.12.031.

@article{1331436,
   author = {Buchler, Tomas and Bortlíček, Zbyněk and Poprach, Alexandr and Pavlík, Tomáš and Veskrnova, Veronika and Honzirkova, Michaela and Zemanova, Milada and Fiala, Ondrej and Kubáčková, Kateřina and Slabý, Ondřej and Svoboda, Marek and Vyzula, Rostislav and Dušek, Ladislav and Melichar, Bohuslav},
   article_location = {Amsterdam},
   article_number = {3},
   doi = {http://dx.doi.org/10.1016/j.eururo.2015.12.031},
   keywords = {Renal cell carcinoma; Targeted therapy; Complete response; Survival},
   language = {eng},
   issn = {0302-2838},
   journal = {European Urology},
   title = {Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis.},
   volume = {70},
   year = {2016}
}

TY  - JOUR
ID  - 1331436
AU  - Buchler, Tomas - Bortlíček, Zbyněk - Poprach, Alexandr - Pavlík, Tomáš - Veskrnova, Veronika - Honzirkova, Michaela - Zemanova, Milada - Fiala, Ondrej - Kubáčková, Kateřina - Slabý, Ondřej - Svoboda, Marek - Vyzula, Rostislav - Dušek, Ladislav - Melichar, Bohuslav
PY  - 2016
TI  - Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis.
JF  - European Urology
VL  - 70
IS  - 3
SP  - 469-475
EP  - 469-475
PB  - Elsevier Science Inc.
SN  - 03022838
KW  - Renal cell carcinoma
KW  - Targeted therapy
KW  - Complete response
KW  - Survival
N2  - BACKGROUND: It is currently not known whether treatment with anti-vascular endothelial growth factor agents for metastatic renal cell carcinoma (mRCC) can be safely discontinued in patients achieving a complete response (CR). OBJECTIVE: To assess outcomes for patients with mRCC achieving CR on targeted therapy (TT) and the survival of patients discontinuing TT after CR. DESIGN, SETTING, AND PARTICIPANTS: A national registry was used to identify patients achieving CR during first-line TT using bevacizumab, sunitinib, sorafenib, or pazopanib. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Relationships with outcomes were analysed using a log-rank test. RESULTS AND LIMITATIONS: A total of 100 patients achieving CR were identified out of 2803 patients. The median time to CR was 10.1 mo. Median progression-free survival (PFS) from TT initiation was 3.8 yr (95% confidence interval [CI] 2.9-4.6 yr) and the 5-yr overall survival (OS) was 80% (95% CI 70-91%). Patients discontinuing TT within 1 mo after achieving CR and those continuing TT beyond CR had similar OS (CI for difference in 2-yr post-CR OS -13% to 19%; p=0.3) and PFS (CI for difference in 2-yr post-CR PFS -29% to 17%; p=0.7). The limitations include the retrospective, registry-based data analysis. CONCLUSIONS: Achievement of CR on TT for mRCC was associated with excellent long-term prognosis. No significant differences in post-CR survival were observed between patients discontinuing TT after the date of CR and those who continued on TT, although the wide CIs cannot exclude important differences between the groups. PATIENT SUMMARY: According to this registry-based analysis, patients with metastatic renal cancer with no signs of disease (complete response) after treatment with targeted agents experience excellent long-term survival even if the treatment does not continue beyond the date of complete response.
ER  -

BUCHLER, Tomas, Zbyněk BORTLÍČEK, Alexandr POPRACH, Tomáš PAVLÍK, Veronika VESKRNOVA, Michaela HONZIRKOVA, Milada ZEMANOVA, Ondrej FIALA, Kateřina KUBÁČKOVÁ, Ondřej SLABÝ, Marek SVOBODA, Rostislav VYZULA, Ladislav DUŠEK a Bohuslav MELICHAR. Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis. \textit{European Urology}. Amsterdam: Elsevier Science Inc., 2016, roč.~70, č.~3, s.~469-475. ISSN~0302-2838. Dostupné z: https://dx.doi.org/10.1016/j.eururo.2015.12.031.

Podrobný výpis o publikaci